Upadacitinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB15091 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 12 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 2 | brachydactyly-syndactyly syndrome | KG + DL |
| 3 | indolent plasma cell myeloma | KG + DL |
| 4 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 5 | heparin cofactor 2 deficiency | KG + DL |
| 6 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 7 | plasma cell myeloma | KG + DL |
| 8 | Mills syndrome | KG + DL |
| 9 | amyotrophic lateral sclerosis | KG + DL |
| 10 | axial spondylometaphyseal dysplasia | KG + DL |
| 11 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 12 | antithrombin deficiency type 2 | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.